Cathepsin Inhibitors Market Regional Analysis
North America cathepsin inhibitors market is expected to hold a dominant position in the global cathepsin inhibitors market, owing to the high prevalence of disease such as cancer, which will increase demand for novel cancer treatment approaches such as cathepsin inhibitors in region.
For instance, according to the data published by National Cancer Institute, it was estimated that in 2018, around 1,735,350 new cases of cancer will be diagnosed in the U.S. and around 609,640 people will die from the disease.
Europe cathepsin inhibitors market is also expected to show a significant growth during the forecast period, owing to frequent research and development activities by key players for the development of new cathepsin inhibitors in the region. For instance, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, is developing RO5459072, a cathepsin S inhibitor, on the immune response to a gluten challenge in volunteers with celiac disease.
Cathepsin Inhibitors Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients